10:33 AM EST - InMed Pharmaceuticals : Filed a Clinical Trial Application in the Netherlands for INM-755, which is being developed for epidermolysis bullosa. Approval of the CTA is expected around the end of November with the first trial (755-101-HV) expected to begin in December. This trial will test two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. Following the completion of this trial, the company expects to initiate trial 755-102-HV, which would test INM-755 on eight healthy volunteers with small wounds. InMed Pharmaceuticals
shares T.IN are trading down $0.01 at $0.25.
